Ian D. Plumb

Ian D. Plumb

Auto-generated profile, based on publicly available information

Ian D. Plumb

Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention , Atlanta, GA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2022 in MMWR. Morbidity and Mortality Weekly Report
Verified
Journal Article
Open access
IPIan D. Plumb
Ian D. Plumb
LFLeora R. Feldstein
Leora R. Feldstein
EBEric Barkley
Eric Barkley
APAlexander B. Posner
Alexander B. Posner
HBHoward S. Bregman
Howard S. Bregman
JGJacqueline L. Gerhart
Jacqueline L. Gerhart
This report describes COVID-19 mRNA vaccination effectiveness in preventing COVID-19 hospitalizations among people previously infected.

23 August 2019 in MMWR. Morbidity and Mortality Weekly Report
Verified
Journal Article
Closed access
IPIan D. Plumb
Ian D. Plumb
CSColin A. Schwensohn
Colin A. Schwensohn
LGLaura Gieraltowski
Laura Gieraltowski
STSelam Tecle
Selam Tecle
ZSZachary D. Schneider
Zachary D. Schneider
CFCindy R. Friedman
Cindy R. Friedman
This report summarizes an investigation of a multistate multidrug resistant Salmonella outbreak in Mexico and the United States.

31 May 2023 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
MGMichael Gottlieb
Michael Gottlieb
ESErica S Spatz
Erica S Spatz
HYHuihui Yu
Huihui Yu
LWLauren E Wisk
Lauren E Wisk
JEJoann G Elmore
Joann G Elmore
RWRobert A Weinstein
Robert A Weinstein
The prevalence, incidence, and interrelationships of persistent symptoms after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection vary. There are limited data on specific phenotypes of persistent symptoms. Using latent class analysis (LCA) modeling, we sought to identify whether specific phenotypes of COVID-19 were present 3 months and 6 months post-infection. This was a multicenter study of symptomatic adults tested for SARS-CoV-2 with prospectively collected data on general symptoms and fatigue-related symptoms up to 6 months postdiagnosis. Using LCA, we identified symptomatically homogenous groups among COVID-positive and COVID-negative participants at each time period for both general and fatigue-related symptoms. Among 5963 baseline participants (4504 COVID-positive and 1459 COVID-negative), 4056 had 3-month and 2856 had 6-month data at the time of analysis. We identified 4 distinct phenotypes of post-COVID conditions (PCCs) at 3 and 6 months for both general and fatigue-related symptoms; minimal-symptom groups represented 70% of participants at 3 and 6 months. When compared with the COVID-negative cohort, COVID-positive participants had higher occurrence of loss of taste/smell and cognition problems. There was substantial class-switching over time; those in 1 symptom class at 3 months were equally likely to remain or enter a new phenotype at 6 months. We identified distinct classes of PCC phenotypes for general and fatigue-related symptoms. Most participants had minimal or no symptoms at 3 and 6 months of follow-up. Significant proportions of participants changed symptom groups over time, suggesting that symptoms present during the acute illness may differ from prolonged symptoms and that PCCs may have a more dynamic nature than previously recognized. Clinical Trials Registration. NCT04610515.

25 February 2022 in MMWR. Morbidity and Mortality Weekly Report
Verified
Journal Article
Closed access
BLBrian Lefferts
Brian Lefferts
IBIan Blake
Ian Blake
DBDana Bruden
Dana Bruden
MHMelissa B. Hagen
Melissa B. Hagen
EHEllen Hodges
Ellen Hodges
IPIan D. Plumb
Ian D. Plumb
This report describes the percentage of positive antigen test results following COVID-19 isolation.

1 April 2018 in The Pediatric Infectious Disease Journal
Verified
Journal Article
Closed access
IPIan D. Mbbs Plumb
Ian D. Mbbs Plumb
KLK. Danielle Lecy
K. Danielle Lecy
RSRosalyn Singleton
Rosalyn Singleton
MEMichael C. Engel
Michael C. Engel
MHMatthew Hirschfeld
Matthew Hirschfeld
MBMichael G. Bruce
Michael G. Bruce
Background: Invasive infections from Haemophilus influenzae serotype a (Hia) have been reported with increasing frequency, especially among indigenous populations. However, there are limited population-based studies of clinical severity. We studied invasive Hia infections in Alaska to determine clinical characteristics, mortality and sequelae. Methods: We defined an invasive Hia infection as the first detection of Hia from a usually sterile site in a child <10 years of age from Alaska. We identified cases using the Alaska Invasive Bacterial Diseases Surveillance System and reviewed medical charts up to 2 years after reported illness. Results: We identified invasive Hia infections in 36 children, 28 (78%) <1 year old, 34 (94%) living in an Alaskan village and 25 (69%) without documented underlying illness. Overlapping clinical presentations included meningitis in 15 children (42%); bacteremia and pneumonia in 10 children (28%); and bone, joint or soft tissue infections in 10 children (22%). In 4 other children, no source of invasive infection was identified. Intensive care was provided for 11 children (31%); 12 children (33%) required surgical intervention. One year after infection, 4 children (11%) had died from Hia, and 5 children (14%) had ongoing neurologic sequelae. Conclusions: Invasive Hia infections in Alaska occurred predominantly in Alaska Native infants in rural communities. Although one-third of children had preexisting conditions, most cases occurred without known comorbidity. Clinical syndromes were frequently severe. One year after infection, 1 in 4 children had either died or had neurologic sequelae. An effective vaccine would prevent significant morbidity and mortality in affected populations.

1 July 2022 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
MTMark W Tenforde
Mark W Tenforde
ODOwen J Devine
Owen J Devine
HRHeather E Reese
Heather E Reese
BSBenjamin J Silk
Benjamin J Silk
AIA Danielle Iuliano
A Danielle Iuliano
JBJeanne Bertolli
Jeanne Bertolli
Background: Although most adults infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) fully recover, a proportion have ongoing symptoms, or post-COVID conditions (PCC), after infection. The objective of this analysis was to estimate the number of United States (US) adults with activity-limiting PCC on 1 November 2021.Methods: We modeled the prevalence of PCC using reported infections occurring from 1 February 2020 to 30 September 2021, and population-based, household survey data on new activity-limiting symptoms ≥1 month following SARS-CoV-2 infection. From these data sources, we estimated the number and proportion of US adults with activity-limiting PCC on 1 November 2021 as 95% uncertainty intervals, stratified by sex and age. Sensitivity analyses adjusted for underascertainment of infections and uncertainty about symptom duration.Results: On 1 November 2021, at least 3.0–5.0 million US adults, or 1.2%–1.9% of the US adult population, were estimated to have activity-limiting PCC of ≥1 month’s duration. Population prevalence was higher in females (1.4%–2.2%) than males. The estimated prevalence after adjusting for underascertainment of infections was 1.7%–3.8%.Conclusions: Millions of US adults were estimated to have activity-limiting PCC. These estimates can support future efforts to address the impact of PCC on the US population.